PTC Therapeutics Statistics
Share Statistics
PTC Therapeutics has 77.13M shares outstanding. The number of shares has increased by 1.94% in one year.
| Shares Outstanding | 77.13M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 74.46M |
| Failed to Deliver (FTD) Shares | 354 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 4.89M, so 6.34% of the outstanding shares have been sold short.
| Short Interest | 4.89M |
| Short % of Shares Out | 6.34% |
| Short % of Float | 6.56% |
| Short Ratio (days to cover) | 5.83 |
Valuation Ratios
The PE ratio is -3.29 and the forward PE ratio is -12.12.
| PE Ratio | -3.29 |
| Forward PE | -12.12 |
| PS Ratio | 2.2 |
| Forward PS | 5.2 |
| PB Ratio | -2.52 |
| P/FCF Ratio | -7.39 |
| PEG Ratio | n/a |
Enterprise Valuation
PTC Therapeutics Inc. has an Enterprise Value (EV) of 2.48B.
| EV / Earnings | -3.95 |
| EV / Sales | 2.64 |
| EV / EBITDA | -7.5 |
| EV / EBIT | -7.09 |
| EV / FCF | -8.88 |
Financial Position
The company has a current ratio of 2.02, with a Debt / Equity ratio of -2.56.
| Current Ratio | 2.02 |
| Quick Ratio | 1.97 |
| Debt / Equity | -2.56 |
| Total Debt / Capitalization | 163.96 |
| Cash Flow / Debt | -0.08 |
| Interest Coverage | -2.7 |
Financial Efficiency
Return on equity (ROE) is 0.77% and return on capital (ROIC) is -22.3%.
| Return on Equity (ROE) | 0.77% |
| Return on Assets (ROA) | -0.33% |
| Return on Capital (ROIC) | -22.3% |
| Revenue Per Employee | 949.21K |
| Profits Per Employee | -634.21K |
| Employee Count | 988 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 2.14 |
Taxes
| Income Tax | -69.51M |
| Effective Tax Rate | 0.1 |
Stock Price Statistics
The stock price has increased by 63.61% in the last 52 weeks. The beta is 0.63, so PTC Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.63 |
| 52-Week Price Change | 63.61% |
| 50-Day Moving Average | 42.3 |
| 200-Day Moving Average | 35.01 |
| Relative Strength Index (RSI) | 55.32 |
| Average Volume (20 Days) | 829.08K |
Income Statement
In the last 12 months, PTC Therapeutics had revenue of $937.82M and earned -$626.60M in profits. Earnings per share was $-8.37.
| Revenue | 937.82M |
| Gross Profit | 872.34M |
| Operating Income | -349.40M |
| Net Income | -626.60M |
| EBITDA | -330.34M |
| EBIT | -349.40M |
| Earnings Per Share (EPS) | -8.37 |
Balance Sheet
The company has $594.00M in cash and $2.23B in debt, giving a net cash position of -$1.64B.
| Cash & Cash Equivalents | 594.00M |
| Total Debt | 2.23B |
| Net Cash | -1.64B |
| Retained Earnings | -3.28B |
| Total Assets | 1.84B |
| Working Capital | 670.84M |
Cash Flow
In the last 12 months, operating cash flow was -$158.42M and capital expenditures -$120.62M, giving a free cash flow of -$279.04M.
| Operating Cash Flow | -158.42M |
| Capital Expenditures | -120.62M |
| Free Cash Flow | -279.04M |
| FCF Per Share | -3.73 |
Margins
Gross margin is 93.02%, with operating and profit margins of -37.26% and -66.81%.
| Gross Margin | 93.02% |
| Operating Margin | -37.26% |
| Pretax Margin | -74.23% |
| Profit Margin | -66.81% |
| EBITDA Margin | -35.22% |
| EBIT Margin | -37.26% |
| FCF Margin | -29.75% |
Dividends & Yields
PTCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -18.02% |
| FCF Yield | -7.79% |
Analyst Forecast
The average price target for PTCT is $56, which is 20.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $56 |
| Price Target Difference | 20.6% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | -1.5 |
| Piotroski F-Score | 3 |